Intellia Therapeutics biopharmaceuticals

Intellia Therapeutics is a leading clinical-stage biotechnology company focused on developing curative genome editing treatments. The company utilizes CRISPR/Cas9 technology to create precisely targeted therapies for patients with genetically defined diseases. Founded by pioneers in the field, including Nobel laureate Jennifer Doudna, Intellia is at the forefront of the genomic medicine revolution.

Headquartered in Cambridge, Massachusetts, Intellia operates primarily within the United States, where its core research, development, and initial clinical manufacturing processes are located. The company maintains significant partnerships with global pharmaceutical leaders to expand the reach and scale of its therapeutic pipeline. As a publicly traded entity on the NASDAQ, its ownership is distributed among institutional and private investors, maintaining its independence as a focused innovator in the biotech sector.